The second edition of the X-omics festival took place online, on September 28th 2020. This event contained a keynote lecture, lectures from investigators and technology pitches. We thank all the speakers, the sponsors and the participants and look forward to future events.
You can find the recordings of this event on our YouTube channel. More details about the speakers and a summary of their presentations with highlights/key take home messages can be found below.
The keynote speaker Tim Hubbard (King’s College London & Genomics England) introduced the UK's 100,000 genomes project which set out to mainstream whole genome sequencing for treatment into the UK National Health Service (NHS). Genomics England, set up in 2013 to deliver the project, established sequencing and interpretation pipelines to enable whole genome sequences (WGS) to be analyzed for rare diseases and cancer patients with individual reports returned to clinicians. Following the successful completion of the project, the UK is establishing the NHS Genome Medicine Service which will sequence another 500,000 whole genomes for clinical care over the next 5 years, alongside a commitment to sequence the whole of the research cohort UK Biobank (another 500,000 whole genomes). Tim talked about how data from the project had been made accessible to more than 3,000 researchers through the creation of a ’Trusted Research Environment’ and how this model is being more widely adopted to enable research access to health service data in UK.
Key take home messages
Whether you are a discovery or translational researcher, the GeoMx DSP is the most flexible spatial solution designed to conform to your ever-changing research needs. It allows you to explore biology with more targets (>20,000) and more analytes (RNA & Protein) to get to your publishable discovery data faster. Plus, expand your research scope and/or collaborations to access more sample types. From FFPE and Fresh Frozen to the most challenging sample types, your research is not limited by type of sample leading to broader discovery and faster data.
Bert Wouters (Leiden University) talked about “Novel analytical technologies for metabolomics: more for less". More specifically, he discussed a novel sample-handling platform for high-throughput flow-NMR aiming to triple the sample throughput compared to conventional NMR screening platforms. He shared insights into the design process of the new platform, including the use of segmented-slug flow for sample transfer, the development of a non-intrusive laser sensor to characterize sample transfer, the development of a novel fluoropolymer-based NMR flow cell, and finally, the application of the NMR platform for high-throughput screening of wine samples.
Key take home messages
Bruker’s innovative timsTOF Flex mass spectrometer includes the ability to do MALDI-MS imaging on tissue slices as well as protein and metabolite identification and quantitation on proteins and metabolites extracted from the same tissue slice. In all modes of analysis the timsTOF Pro provides accurate measurements of the collision cross sections of the measured metabolites and proteins, providing an additional dimension of information to correlate spatially resolved information from imaging with detailed identification and quantitation results from LC-MS workflows in an approach we call 4D-SpatialOmx.
Key take home messages
Due to the use of privacy sensitive information, Gary's online presentation can’t be shown.Presentation
During the X-Omics 2020 festival dr. Hans Wessels presented on application of clinical glycoproteomics in research and diagnostics. He shared insights into the technology driving N-glycopeptide profiling in plasma and how acquired site-specific protein glycosylation data is key to understand and detect disease processes. First examples for implementation of glycopeptide-based diagnostics at the Translational Metabolic Laboratory of the Radboudumc were shown to illustrate the translation from research technology into applied patient care.
Key take home messages
Many of the technical challenges that the fields of genomics, proteomics and metabolomics evoke can be addressed by using cloud technology. On demand scalable storage and compute enable cost efficient data handling and analysis. The ability to try new tools in a self-service model helps in staying agile and up to speed with the latest developments in your field.
The challenges mentioned above are even more pronounced in the field of X-omics, where workloads from a heterogeneous field of research domains need to be combined into a manageable data platform. The compute and analytics demands that arise from this combination are heavy and unpredictable.
Microsoft Azure delivers the platform tools to develop and manage a X-omics environment to tackle these problems. From automated data ingestion, data lake, MPP, and catalog options, to specialized sequencing services and an open data science platform, Azure offers tools to enable the X-omics pipeline from data ingestion to model deployment. Since Microsoft Azure has a large third party and open source ecosystem, you can use many of the tools you are used to within the context of this platform
Key take home message
Jenny van Dongen presented an Epigenome-wide Association Study meta-analysis of educational attainment performed within the BBMRI-NL Biobank-based Integrative Omics Study Consortium. The study included >4,000 participants from four Dutch cohorts, and focused on genome-wide DNA methylation (Illumina 450k array) measured in whole bood samples. In addition, transcriptomic (RNA-seq), genomic, and metabolomic data are available within these cohorts. Educational attainment is a key behavioural measure in studies of cognitive and physical health, and socioeconomic status. The study identified 58 CpGs associated with educational attainment at loci characterized by pleiotropic functions shared with neuronal, immune and developmental processes. Associations overlapped with those for smoking behaviour, but remained after accounting for smoking at many CpGs: Effect sizes were on average 28% smaller and genome-wide significant at 11 CpGs after adjusting for smoking and were 62% smaller in never smokers. Sources and biological implications of education-related methylation differences were examined, including correlations with maternal prenatal folate, smoking and air pollution signatures, and associations with gene expression in cis, dynamic methylation in foetal brain, and correlations between blood and brain.
Key take home messages:
Due to the use of privacy sensitive information, Clara's presentation can’t be shown.
In the closing talk of the day, Ahmed Mahfouz (Leiden University Medical Center) presented the work of his group on using transcriptomic data to better understand the role of genetic variation in brain function and disease. He first presented their work on Parkinson’s disease linking findings from genetic studies to spatial expression data from the Allen Human Brain Atlas to key pathways and mechanisms that likely underly the vulnerability of brain regions to pathologies.
Next, Ahmed showed how his group is tackling the limitation in the number of genes measured simultaneously with single-cell spatial transcriptomics techniques. They recently developed SpaGE, a method which integrates spatial and single-cell RNA-sequencing data to predict genome-wide expression patterns in their spatial context.Link 1 Link 2
Link 1: Keo, A., Mahfouz, A., Ingrassia, A.M.T. et al. Transcriptomic signatures of brain regional vulnerability to Parkinson’s disease. Commun Biol 3, 101 (2020).
Link 2: Tamim Abdelaal, Soufiane Mourragui, Ahmed Mahfouz, Marcel J T Reinders, SpaGE: Spatial Gene Enhancement using scRNA-seq, Nucleic Acids Research, gkaa740
Key take-home messages
Back in 1997, Tim Hubbard joined the Wellcome Trust Sanger Institute to become Head of Human Genome Analysis, where he was one of the organizers of the sequencing of the human genome. Two years later, he co-founded the Ensembl project to analyze, organize and provide access to the human genome.
From 2007 he led the GENCODE project to annotate the structure of all human genes. Tim Hubbard was the Sanger Institute PI of the Genome Reference Consortium and he became Head of the Informatics division
After the announcement of the 100,000 genomes project 2012, he was seconded part-time as a specialist advisor for genomics to NHS England leading up to the creation of Genomics England.
In October 2013 Tim Hubbard was appointed Professor of Bioinformatics and Head of the Department of Medical & Molecular Genetics at King's College London and Director of Bioinformatics for King's Health Partners with a part-time secondment as Head of Genome Analysis at Genomics England.
In 2018 he was also appointed as Associate Director (King's) for the Health Data Research London Site.
Wei Wu is an assistant professor in the Department of Pharmaceutical Sciences in Utrecht University. With a niche in extracellular (affinity) proteomics, her research focuses on dissecting intercellular crosstalk, that is mediated through secretion and/or signalling at the plasma membrane interface.
Tony’s career has spanned from academic research into industry research instrumentation. His career of scientific experience has been with technologies such as Gene Expression, Gene Sequencing, Microscopy, Image Analysis and Digital Pathology.
Bert Wouters has conducted his doctoral research at the Free University of Brussels (under the supervision of Prof. Eeltink and Prof. Desmet). During his research, he developed advanced strategies for one-, two-, and three-dimensional LC and novel approaches to prototype microfluidic devices for high-pressure liquid chromatography. After his PhD, he started working as a postdoctoral researcher at the University of Amsterdam under the supervision of Prof. Schoenmakers, focussing on the development of a microfluidic immobilized-enzyme reactor implemented in-line in a high-throughput LC×LC workflow. Currently, he is working as a postdoctoral researcher at Leiden University in the group of Prof. Thomas Hankemeier on the topics of microfluidic sample-preparation and sample-transfer, high-throughput automated techniques, and flow-NMR spectroscopy.
Dr. Gary Kruppa is the vice president of proteomics at Bruker Daltonics Inc. He earned his Ph.D. in chemical physics at the California institute of Technology in 1988, and subsequently has worked in the field of mass spectrometry instrumentation and applications for over 30 years. During that time he has led successful efforts to commercialize applications of mass spectrometry in metabolomics, microbiology, and proteomics, and currently leads a global team of applications scientists and developers working on new applications of mass spectrometry in the field of proteomics.
Dr. Hans Wessels specializes in translational clinical proteomics driving further development of emerging technologies contributing to healthcare. His professional career started as proteomics specialist at the Radboud University Medical Center in 2003 working on inborn errors of metabolism and biochemistry of novel microorganisms. In this time, he was key to establish the core proteomics facility of the Radboudumc. From 2010-2015, he performed his PhD research at the Nijmegen Center for Mitochondrial Disorders where he conceived and applied novel methods to study mitochondrial complexomes. Since then, he is building his own line of research on the importance of proteoforms in disease pathology at the Translational Metabolic Laboratory. Innovative projects include the development and implementation of Top-Down proteomics and Glycoproteomics using trapped ion mobility tandem mass spectrometry for translational research and patient care.
Ruben Pool studied Biomedical Physics at the University of Amsterdam and continued with a PhD in molecular biophysics at the AMOLF institute. After completion he worked as a data scientist in a healthcare startup and continued his career as a cloud solution architect at Microsoft. In this role for several years now, Ruben has been working with universities, research institutes and hospitals, helping them with technical challenges by designing solutions based on cloud technology.
Jenny van Dongen is an assistant professor at the department of Biological Psychology at the VU Amsterdam. She works with data from the Netherlands Twin Register to study the causes of individual differences in DNA methylation and the connections between epigenetic mechanisms and behavior and health. Dr. van Dongen has a Bachelor’s degree in Biology and Master’s degree in Neuroscience, and obtained her PhD at the VU Amsterdam in 2015. Within the BBMRI-NL BIOS consortium (http://www.bbmri.nl/acquisition-use-analyze/bios/), she has worked together with multiple Dutch biobanks to study the interplay between genome, epigenome, transcriptome, and complex traits, and led an epigenome-wide association study meta-analysis of educational attainment (https://www.nature.com/articles/s41539-018-0020-2).
Roland Kanaar (1961) is professor of Molecular Genetics and head of the Molecular Genetics department at the Erasmus University Medical Center. His research focuses on the molecular mechanisms and biological and physiological relevance of the DNA damage response. His work integrates interdisciplinary approaches from molecules to cancer patients. His research group uses fundamental insights into how the DNA damage response works and how it can be manipulated to enhance and design cancer treatments. In 2002 he was elected a member of the European Molecular Biology Organization (EMBO) and in 2013 he was elected to the Royal Netherlands Academy of Arts and Sciences (KNAW). In 2020 his research team won the "Ammodo Science Award for groundbreaking research" in the natural sciences.
Professor Clara van Karnebeek is head of the metabolic diseases department in the Radboud University Medical Centre in Nijmegen and principal investigator at the Amsterdam University Medical Centres, The Netherlands and the University of British Columbia in Vancouver Canada.
Clara’s work as a pediatrician and biochemical geneticist focuses on early diagnosis and innovative treatment of neurometabolic diseases in a P4-medicine model. Her international team integrates genomic and metabolomics technologies to unravel the cause of degenerative brain conditions in children, discovering novel genetic conditions and treatment targets. She implements this knowledge in the management of her patients, via clinical trials with personalized outcomes. Translating new knowledge into expanded newborn screening, as well as useful information and action for the patient and family, using digital applications, are the ultimate goals of her multi-disciplinary team’s effort.
She is the Director of United for Metabolic Diseases (www.umd.nl), a Dutch consortium uniting all 6 academic metabolic expertise centers and the patient organizations to optimize research and care.
She published over 170 peer-reviewed journal articles, multiple clinical guidelines and chapters in textbooks. Clara is regularly invited for keynote lectures at international conferences for professional societies in neurology, genetics and pediatrics. She is a dedicated teacher and mentor for clinical and research trainees at different stages. For her contributions to research and clinical care and commitment to translational science she received the Canadian Organization for Rare Diseases Scientist Award.
Ahmed Mahfouz is an assistant professor at the Human Genetics Department at the Leiden University Medical Center. His research combines machine learning and statistical models to analyze single cell data. He aims to use these approaches to study the effects of genetic variation on cellular diversity.
NanoString provides life science tools from discovery to translational research. The company's nCounter Analysis System offers a cost-effective way to easily profile hundreds of genes, proteins, miRNAs, simultaneously with high sensitivity and precision, for basic research and translational applications, especially in the fields on Immunology and Oncology.
The innovative GeoMx™ Digital Spatial Profiler performs whole slide imaging to discover and profile biomarkers, in situ, by digitally quantifying >1600 mRNAs panels (or the full transcriptome) or >90 proteins simultaneously on region of interest on FFPE or Fresh frozen tissue slices.Brochures:
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. Bruker Daltonics, a division of the Bruker Corporation, provides cutting edge mass spectrometry solutions which include MALDI-TOF, UHR-QTOF, Ion Traps, MRMS as well as LC and GC systems to solve the most demanding analytical questions presented to these markets today. For more information, please visit: www.bruker.com.
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.Brochures:
Waters Corporation is the world's leading specialty measurement company focused on improving human health and well-being through the application of high-value analytical technologies and industry leading scientific expertise. Our decisions and actions are guided by two simple words – Deliver Benefit. Our founder, Jim Waters, coined these words to encapsulate the idea that we should positively impact our customers, employees, shareholders and society at every opportunity.
Driven by that ethos for over sixty years, Waters has continually pioneered chromatography, mass spectrometry and thermal analysis innovations. Whether it’s discovering new pharmaceuticals, assuring the safety of the world’s food and water supplies, or ensuring the integrity of a chemical entity in production, we are constantly working with our 40,000+ customers to change the world.Brochures:
Shimadzu provides a broad range of analytical instruments indispensable for research, development, and quality control in a variety of market segments such as Food, Beverages and Agriculture; Pharmaceutical; Clinical; Environmental; Chemical, Petrochemical, Biofuel and Energy, Plastics and Rubber. Our high-level, sophisticated product range includes Gas Chromatography (GC), Gas Chromatography Mass Spectrometry (GCMS), Liquid Chromatography (LC, HPLC, UHPLC), Liquid Chromatography Mass Spectrometry (LCMS), Ultra-fast Mass Spectrometry (UFMS), Spectroscopy, UV-Vis-NIR, FTIR, Atomic Absorption Spectroscopy (AAS) and Energy Dispersive X-ray Fluorescence Spectroscopy, Inductively Coupled Plasma Emission Spectroscopy (ICP-OES), elemental and surface analysis systems, Particle Size, Life Science Lab Instruments, Total Organic Carbon Analysis (Sum Parameters), Material Testing and Measuring Technology. Our offer is rounded by Columns and Consumables, Analytical Standards, Diagnostic reagent kits and Data management and Software systems.
Health-RI is the Dutch non-profit foundation supporting a public private partnership of organizations that want to realize a national health-data infrastructure. More than 70 organizations involved in health research and care endorse our efforts..
Build an integrated health data research infrastructure accessible for researchers, citizens and care providers.
Facilitate and foster the optimal use of knowledge, tools, facilities, health data and samples to enable a learning healthcare system and accelerate sustainable and affordable personalized medicine and health.
How we operate
Health-RI follows three lines of action
1. Collective action: optimizing the conditions for building and maintaining a national health data infrastructure;
2. Building a national health data infrastructure: fostering and facilitating initiatives and collaborations directed at developing health data infrastructure;
3. Providing mature services: supporting researchers and data managers by making infrastructure services, tools and data easy to locate, access and use;
PharmaFluidics introduces the silicon revolution in liquid chromatography. The micro-Chip Pillar Array (µPAC™) column overcomes the physical limits of any packed bed alternative. The µPAC™ columns feature a perfectly ordered separation bed of free-standing pillars ensuring excellent separation power, unprecedented reproducibility and unrivalled robustness.
Whether you are analyzing trace amounts of compounds in complex biological samples for proteomics, metabolomics or Lipidomics, or whether you are looking for subtle modifications in monoclonal antibodies: use plug-and-play µPAC™ columns to boost your biomarker and life sciences research. Our µPAC™ columns are compatible with all standard nano-LC equipment.
From Sample to Biology
SCIEX has a proven record of cutting edge Omics research technologies helping life science researchers to faster translate analytical information into biological knowledge. Our workflow and technology advancements are driven through collaboration with trusted partners among most globally renowned Omics experts. As a result, we provide you with continuously more productive and reliable solutions to discover, identify, quantitate and interpret key genes, proteins, lipids and metabolites in complex systems biology.
Leveraging Multi-Omics Research to See What’s Beyond the Genome
Combining innovative lab technologies with cloud-based, next-generation bioinformatics, our goal is to help you leverage knowledge from multiple omics fields and gain faster, more comprehensive insight into relevant biological information.
Together, let’s foster the multi-omics revolution and discover what’s beyond the genome.Brochures:
About PacBio and SMRT Sequencing
PacBio® Single Molecule, Real-Time (SMRT®) Sequencing delivers highly accurate long reads (HiFi reads) for the most comprehensive view of human genetic variation at an affordable price. The Sequel® II System, has the ability to resolve some of the most challenging regions of the genome with end-to-end solutions like WGS, full-length RNA and targeted sequencing.
Watch the short video to learn about SMRT Sequencing.
Contact us with your questions about SMRT Sequencing and using HiFi reads for your human genomics projects.